Clinical Experience with 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung Cancer

Keyphrases

• Clinical Experience 100%
• Epidermal Growth Factor Receptor 100%
• Non-small Cell Lung Cancer (NSCLC) 100%
• Erlotinib 100%
• Overall Survival 42%
• Drug Discontinuation 28%
• Starting Dose 28%
• South America 14%
• Biological Agents 14%
• Clinical Evolution 14%
• Maximum Tolerated Dose 14%
• Response Rate 14%
• Retrospective Review 14%
• Progression-free Survival 14%
• Metastatic Non-small Cell Lung Cancer 14%
• Rash 14%
• Diarrhea 14%
• EGFR mutation 14%
• Targeted Therapy 14%
• Median Progression-free Survival 14%
• Brain Metastases 14%
• Cancer Causes 14%
• Cancer Mortality 14%
• Metastatic NSCLC 14%
• Phase I Study 14%
• Ethnic Background 14%
• Radiological Assessment 14%
• Optimal Biological Dose 14%
• Toxicity Grades 14%
• First Diagnosis 14%
• Exon 21 mutation 14%
• Second-line Treatment 14%
• Clinical Information 14%
• Adjusted Dose 14%
• South American Population 14%
• Evolution Evaluation 14%
• Del19 14%
• Epidermal Growth Factor Receptor Inhibitors 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Erlotinib 100%
• Epidermal Growth Factor Receptor 100%
• Overall Survival 42%
• Progression Free Survival 28%
• Rash 14%
• Diarrhea 14%
• Brain Metastasis 14%
• Maximum Tolerated Dose 14%
• Cancer Mortality 14%
• Epidermal Growth Factor Receptor Kinase Inhibitor 14%
• Biological Product 14%